Heterogeneity among characteristics of hypereosinophilic syndromes

Helbig, Grzegorz; Moskwa, Andrzej; Hus, Marek; Woźniczka, Krzysztof; Wieczorkiewicz, A; Dziaczkowska-Suszek, Joanna; Soja, Anna; Bartkowska-Chrobok, Aleksandra; Kyrcz‐Krzemień, Sławomira

doi:10.1016/j.jaci.2010.02.024

Cited by 10 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It occurs in several myeloproliferative disorders associated with tyrosine kinase mutations or translocations. Although more common between 20 and 50 years of age, this entity is sometimes encountered in children and is more common in males [18][19][20]. Whereas dermatological, pulmonary and gastrointestinal involvement seems to be more common, the involvement of the cardiovascular system represents the major source of morbidity and mortality [19].…”

Section: Hypereosinophilic Syndromementioning

confidence: 99%

Eosinophilic cardiac disease: Molecular, clinical and imaging aspects

Séguéla

Iriart

Acar

et al. 2015

Archives of Cardiovascular Diseases

View full text Add to dashboard Cite

Eosinophilia may be responsible for cardiac injuries of widely varying severity, from acute myocarditis to endomyocardial fibrosis. In this review, we present both the molecular mechanisms that are responsible for these lesions and their clinical and paraclinical aspects. Numerous aetiologies can lead to severe eosinophilia, but these are mainly represented by hypersensitivity reactions, rheumatological diseases and hypereosinophilic syndrome. Because cardiac involvement may be extremely severe, echocardiography should be always performed in the context of eosinophilia and appropriate therapeutics should be started rapidly in order to limit the progression of the disease.

show abstract

Section: Hypereosinophilic Syndromementioning

confidence: 99%

Eosinophilic cardiac disease: Molecular, clinical and imaging aspects

Séguéla

Iriart

Acar

et al. 2015

Archives of Cardiovascular Diseases

View full text Add to dashboard Cite

show abstract

“…In our study, 42 patients with unexplained, prolonged hypereosinophilia were tested for T‐cell abnormalities, and an aberrant lymphocyte populations were detected in 18 (43%). Three of the 42 studied patients exhibited abnormal T cells in peripheral blood by flow cytometry and their immunophenotypes were shown elsewhere [4, 5]. Herein, we present in details one from these patients with L‐HES.…”

mentioning

confidence: 79%

The proportion of CD3⁻ CD4⁺ T‐cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L‐HES)

Helbig

Wichary

Raźny³

et al. 2010

Scand J Immunol

View full text Add to dashboard Cite

“…HES has been defined by Chusid et al [4] as eosinophilia >1500/mm 3 for >6 months, without any secondary cause and with evidence of tissue damage [4]. It is more common between 20 years and 50 years of age and in men [5]. Two subtypes of HES must be recognized: a lymphocytic variant (L-HES) and a myeloproliferative one.…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic myocarditis and hypereosinophilic syndrome

Boussir¹,

Ghalem²,

Ismaili³

et al. 2017

Journal of the Saudi Heart Association

View full text Add to dashboard Cite

Hypereosinophilic syndrome (HES) is a heterogeneous group of hematological disorders characterized by a chronic, unexplained hypereosinophilia with tissue damage. Cardiac involvement occurs in ∼20% of patients with HES and represents a major turning point. Cardiac injuries related to eosinophilia are divided into three chronological phases: eosinophilic infiltration, thrombosis, and fibrosis. We report a case of a 33-year-old woman diagnosed with HES, with pulmonary and gastrointestinal involvement and eosinophilic myocarditis in cardiogenic shock. The evolution was favorable with dobutamine, anticoagulation, corticosteroids, and later, β-blockers and angiotensin-converting enzyme inhibitors. Cardiac involvement in HES is rare but carries a poor prognosis. Corticosteroids are considered by many to be the mainstay of treatment. Although new treatments have been suggested, only a few seem promising.

show abstract

Heterogeneity among characteristics of hypereosinophilic syndromes

Cited by 10 publications

References 6 publications

Eosinophilic cardiac disease: Molecular, clinical and imaging aspects

Eosinophilic cardiac disease: Molecular, clinical and imaging aspects

The proportion of CD3⁻ CD4⁺ T‐cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L‐HES)

Eosinophilic myocarditis and hypereosinophilic syndrome

Contact Info

Product

Resources

About

Heterogeneity among characteristics of hypereosinophilic syndromes

Cited by 10 publications

References 6 publications

Eosinophilic cardiac disease: Molecular, clinical and imaging aspects

Eosinophilic cardiac disease: Molecular, clinical and imaging aspects

The proportion of CD3− CD4+ T‐cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L‐HES)

Eosinophilic myocarditis and hypereosinophilic syndrome

Contact Info

Product

Resources

About

The proportion of CD3⁻ CD4⁺ T‐cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L‐HES)